Formulation scientists are behind the conversion of active pharmaceutical ingredients (API) into stable, bioavailable, and commercially viable dosage forms, rarely a simple process. Image Credit: ...
Researchers at the University of Toronto say they have successfully tested the use of machine learning models to guide the design of long-acting injectable drug formulations. The potential for machine ...
The MarketWatch News Department was not involved in the creation of this content. AI-driven robotics platform reduces drug formulation development time from years to months SACRAMENTO, Calif., May 19, ...
Scientists at the University of Toronto have successfully tested the use of machine learning models to guide the design of long-acting injectable drug formulations. The potential for machine learning ...
Scientists have successfully tested the use of machine learning models to guide the design of long-acting injectable drug formulations. The potential for machine learning algorithms to accelerate drug ...
Suzanne Jansen, MSc, PharmD, ICON, says early-phase clinical success depends on flexible, simple formulations that support wide dose ranges, matching placebos, and robust stability. Formulations are ...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable ...
Type-3 New Drug Applications, focusing on new dosage forms, dominate the 505(b)(2) pathway approvals, with injectable formulations being the largest category. Stability and manufacturing consistency ...
Early on, the drug substance (DS) manufacturer will provide a wealth of preliminary characterization data. And if the drug is active in early nonclinical and preclinical testing, a larger quantity of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results